Clinical Outcomes after Proton Partial-Breast Radiotherapy for Early-Stage, Hormone Receptor-Positive Breast Cancer: 3-Year Outcomes of a Phase II Trial

被引：3

作者：

Choi, I. J. ^{[1
]}

Prabhu, K., Jr. ^{[2
]}

Hartsell, W. F. ^{[3
]}

Sinesi, C. C. ^{[4
]}

Vargas, C. E. ^{[5
,6
]}

Benda, R. K. ^{[7
]}

Cahlon, O. ^{[8
]}

Chang, A. L. ^{[9
]}

机构：

[1] New York Proton Ctr, New York, NY USA

[2] Procure Proton Therapy Ctr, Oklahoma City, OK USA

[3] Northwestern Med Chicago Proton Ctr, Warrenville, IL USA

[4] Hampton Univ, Proton Therapy Inst, Hampton, VA 23668 USA

[5] Mayo Clin, Scottsdale, AZ USA

[6] Mayo Clin Arizona, Dept Radiat Oncol, Phoenix, AZ USA

[7] Boca Raton Reg Hosp, Boca Raton, FL USA

[8] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[9] Calif Protons Canc Therapy Ctr, San Diego, CA USA

来源：

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2019年 / 105卷 / 01期

关键词：

D O I：

10.1016/j.ijrobp.2019.06.659

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2042

引用

页码：E19 / E19

页数：1

共 50 条

[31] A Phase II Study of Once a Day Partial Breast Irradiation (PBI) for Early-Stage or Noninvasive Breast Cancer: Early Toxicity Outcomes
Cahlon, O.
Ho, A. Y.
Siu, C. T.
McCormick, B.
Recht, A.
Taghian, A. G.
Powell, S. N.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (03): : E15 - E15
[32] Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer.
Sardesai, Sagar D.
Kassem, Mahmoud
Morgan, Evan
Palettas, Marilly
Stephens, Julie
Williams, Nicole Olivia
Stover, Daniel G.
Van Deusen, Jeffery
Wesolowski, Robert
Lustberg, Maryam B.
Ramaswamy, Bhuvaneswari
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[33] INTRAOPERATIVE RADIOTHERAPY IN EARLY-STAGE BREAST CANCER: RESULTS OF THE MONTPELLIER PHASE II TRIAL
Lemanski, Claire
Azria, David
Gourgon-Bourgade, Sophie
Gutowski, Marian
Rouanet, Phillippe
Saint-Aubert, Bernard
Ailleres, Norbert
Fenoglietto, Pascal
Dubois, Jean-Bernard
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 76 (03): : 698 - 703
[34] Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer
Zhu, Lizhe
Ma, Nan
Wang, Bin
Zhou, Can
Yan, Yu
Wang, Ke
He, Jianjun
Ren, Yu
ONCOLOGY LETTERS, 2019, 17 (06) : 5469 - 5480
[35] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
Yan, Yi-Dan
Fu, Jie
Gu, Zhi-Chun
Lu, Jin-Song
Su, Ying-Jie
Lin, Hou-Wen
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2023, 45 (01) : 184 - 190
[36] Neratinib for the treatment of early-stage, hormone receptor-positive, HER2-overexpressed breast cancer
Jerez, Yolanda
Herrero, Blanca
Arregui, Marta
Moron, Blanca
Martin, Miguel
Echavarria, Isabel
FUTURE ONCOLOGY, 2020, 16 (17) : 1165 - 1177
[37] Adherence to endocrine therapy in patients with hormone receptor-positive early-stage breast cancer: a retrospective study
Yi-Dan Yan
Jie Fu
Zhi-Chun Gu
Jin-Song Lu
Ying-Jie Su
Hou-Wen Lin
International Journal of Clinical Pharmacy, 2023, 45 : 184 - 190
[38] Incident comorbidities in a diverse cohort of women treated for early-stage, hormone receptor-positive breast cancer
Gupta, Tanya
Purington, Natasha
Liu, Mina
Han, Summer
Sledge, George
Schapira, Lidia
Kurian, Allison
CANCER RESEARCH, 2021, 81 (04)
[39] A phase II trial of cabozantinib in hormone receptor-positive breast cancer with bone metastases.
Xu, Jing
Higgins, Michaela Jane
Tolaney, Sara M.
Come, Steven E.
Smith, Matthew Raymond
Fornier, Monica N.
Mahmood, Umar
Yeap, Beow Y.
Chabner, Bruce Allan
Isakoff, Steven J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[40] Prognostic Tests in Early-Stage Hormone Receptor-Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care
LeVasseur, Nathalie
Gelmon, Karen A.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (10) : 1816 - +

← 1 2 3 4 5 →